AstraZeneca signs an agreement with Tatarstan to develop R&D projects

| By | AstraZeneca, Drug Development, R&D, Tatarstan

At the Russian-British business forum, Tatarstan Investment Development Agency and AstraZeneca, a UK pharmaceutical company, signed a cooperation agreement for the development of R&D projects in the pharmaceutical industry.

The agreement provides for sharing the experience in the area of R&D projects and exploring the opportunities of joint educational projects. The first step in this cooperation will be the establishment of a working group to study the issues of further collaboration.

Irina Ivanishcheva, Corporate Affairs and Legal Director, Russia and Eurasia, at AstraZeneca, said that the research and development are always within the focus of the company.

“A key place in our R&D strategy is held by the partnerships, because sharing the experience opens additional opportunities for the development of research projects in the pharmaceutical industry and creation of new potential drugs. We hope that the agreement signed with the Tatarstan Investment Development Agency will contribute to the development of biomedical research in the region, and will also help to provide new and effective medicines to the patients,” she said.